Paper Details

  1. Home
  2. Paper Details

Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.

Author: DikaEmi, FantiPier Alessandro, MelottiBarbara, PatriziAnnalisa, PiracciniBianca Maria, RiberoSimone, SperandiFrancesca, StaraceMichela

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.

Overview

This study examines the hair and nail side effects of targeted therapies for melanoma, specifically BRAF and MEK inhibitors, finding that hair changes and onycholysis are common side effects.
Paper Details　
Original Abstract of the Article :
Targeted therapies for melanoma have shown clinical benefit in increasing the survival of metastatic patients. Cutaneous adverse events have been reported, but hair and nail data have been rarely detailed. Patients treated with BRAF and MEK inhibitors for metastatic melanoma underwent dermatological...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1684/ejd.2016.2747

データ提供：米国国立医学図書館（NLM）

Melanoma Treatment: A Journey Through the Desert of Side Effects

The fight against melanoma, like a long caravan journey through a harsh desert, often involves navigating side effects of treatment. This research delves into the cutaneous side effects of targeted therapies for metastatic melanoma, focusing on hair and nail changes. The authors meticulously documented the observed adverse effects in patients treated with BRAF and MEK inhibitors, highlighting the challenges faced by patients undergoing these therapies. It's like observing the impact of a desert storm on a fragile ecosystem, understanding the consequences of treatment on the body.

Hair and Nail Changes in Melanoma Treatment

The study found that hair and nail side effects were common in patients receiving targeted therapies for melanoma. It's like a desert landscape, where the wind and sun can change the appearance of plants and rocks. The study highlights the importance of early recognition and management of these side effects, ensuring patient comfort and minimizing the need for dose reduction or discontinuation of treatment.

Managing Side Effects in Melanoma Treatment

This research emphasizes the importance of a holistic approach to melanoma treatment, considering not only the effectiveness of therapies but also the potential side effects. It's like a caravan leader, ensuring the well-being of travelers throughout their journey across the desert. The study highlights the need for close monitoring and communication between patients and their physicians to manage side effects effectively and improve patient outcomes.

Dr.Camel's Conclusion

This research underscores the intricate relationship between melanoma treatment and its impact on the body. It's like a camel caravan navigating a challenging desert, facing both the beauty of the landscape and the harsh realities of the environment. The study emphasizes the importance of understanding and managing side effects to ensure patient well-being and optimize treatment outcomes.

Date :
  1. Date Completed 2017-06-23
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

27019511

DOI: Digital Object Identifier

10.1684/ejd.2016.2747

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.